Table 1.

Clinicopathological characteristics stratified according to TP53 signature status.

	Total		Mutant signature		Wild-type signature		P a
	No. of patients	%	No. of patients	%	No. of patients	%
Samples	333		154	46.3	179	53.8
Age, years (median)							.84
Median	49		49		47.6
Range	24-75		24-72		26-75
AJCC stage							.013
I	8	2.4	5	3.3	3	1.7
IIA	113	33.9	39	25.3	74	41.3
IIB	140	42.0	69	44.8	71	39.7
IIIA	64	19.2	38	24.7	26	14.5
IIIB	8	2.4	3	2.0	5	2.8
T category							.047
T1	48	14.4	19	12.3	29	16.2
T2	192	57.7	82	53.3	110	61.5
T3	93	27.9	53	34.4	40	22.4
Nodal status							.58
Positive	187	56.2	89	57.8	98	54.8
Negative	146	43.8	65	42.2	81	45.3
ER							<.0001
Positive	205	61.6	52	33.8	153	85.5
Negative	125	37.5	102	66.2	23	12.9
NA	3	0.90	0	0.0	3	1.7
PgR							<.0001
Positive	181	54.4	42	27.3	139	77.7
Negative	148	44.4	111	72.1	37	20.7
NA	4	1.2	1	0.3	3	1.7
HER2							.10
Positive	3	0.90	3	2.0	0	0.0
Negative	320	96.1	148	96.1	172	96.1
NA	10	3.0	3	2.0	7	3.9
Grade							<.0001
1	25	7.5	0	0.0	25	14.0
2	132	39.6	26	16.9	106	59.2
3	158	47.5	118	76.6	40	22.4
NA	18	5.4	10	6.5	8	4.5
Intrinsic subtype							<.0001
Luminal A	118	35.4	7	4.6	111	62.0
Luminal B	53	15.9	24	15.6	29	16.2
HER2	20	6.0	14	9.1	6	3.4
Basal	111	33.3	104	67.5	7	3.9
Normal	31	9.3	5	3.3	26	14.5

Abbreviations: AJCC, American Joint Committee on Cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor type 2; NA, not available; PgR, progesterone receptor.

^aChi-square test was used for statistical analysis of patients’ characteristics except for age. Kruskal-Wallis test was used for statistical analysis of patients’ age.